Soleno Therapeutics (NASDAQ:SLNO) Given a $121.00 Price Target at Robert W. Baird

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) has been given a $121.00 price target by research analysts at Robert W. Baird in a research report issued on Friday, July 11th, MarketBeat reports. The firm presently has an "outperform" rating on the stock. Robert W. Baird's price objective suggests a potential upside of 42.59% from the stock's previous close.

Several other equities research analysts have also issued reports on SLNO. Stifel Nicolaus raised their target price on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a report on Friday, March 28th. UBS Group set a $105.00 price target on shares of Soleno Therapeutics in a report on Thursday, March 27th. TD Cowen started coverage on shares of Soleno Therapeutics in a report on Monday, June 23rd. They set a "buy" rating and a $110.00 price objective on the stock. Laidlaw increased their target price on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Finally, Cowen initiated coverage on shares of Soleno Therapeutics in a research report on Monday, June 23rd. They set a "buy" rating for the company. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $108.70.

Soleno Therapeutics Stock Up 1.1%

Shares of NASDAQ SLNO opened at $84.86 on Friday. The stock has a market capitalization of $4.28 billion, a PE ratio of -18.37 and a beta of -2.63. The company has a debt-to-equity ratio of 0.21, a current ratio of 19.64 and a quick ratio of 19.64. The business's fifty day moving average price is $81.62 and its 200-day moving average price is $66.30. Soleno Therapeutics has a one year low of $41.50 and a one year high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.14) by $0.19. On average, equities research analysts anticipate that Soleno Therapeutics will post -3.72 EPS for the current year.

Insider Activity

In other news, insider Patricia C. Hirano sold 3,830 shares of the stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total transaction of $316,970.80. Following the transaction, the insider directly owned 13,206 shares in the company, valued at approximately $1,092,928.56. This represents a 22.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.40% of the company's stock.

Institutional Trading of Soleno Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc lifted its position in Soleno Therapeutics by 9.2% during the fourth quarter. Legal & General Group Plc now owns 23,471 shares of the company's stock valued at $1,055,000 after purchasing an additional 1,983 shares in the last quarter. Emerald Advisers LLC raised its holdings in Soleno Therapeutics by 85.4% during the fourth quarter. Emerald Advisers LLC now owns 580,919 shares of the company's stock valued at $26,112,000 after acquiring an additional 267,585 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Soleno Therapeutics by 13.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 217,550 shares of the company's stock valued at $9,779,000 after acquiring an additional 24,953 shares during the period. Sei Investments Co. raised its holdings in Soleno Therapeutics by 47.0% during the fourth quarter. Sei Investments Co. now owns 16,444 shares of the company's stock valued at $739,000 after acquiring an additional 5,258 shares during the period. Finally, GAMMA Investing LLC raised its holdings in Soleno Therapeutics by 4,377.3% during the first quarter. GAMMA Investing LLC now owns 3,358 shares of the company's stock valued at $240,000 after acquiring an additional 3,283 shares during the period. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.